 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...155156157158159160161162163164165...170171» |
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration Trials. (Pubmed Central) - Sep 13, 2017
Of all prescriptions written by cardiologists for these agents, 20.8% of apixaban and 21.7% of rivaroxaban prescriptions were for a reduced dose; corresponding to a 4.4-fold (16.1% absolute) increase in use of reduced dose apixaban and a 3% relative (0.6% absolute) increase in reduced dose rivaroxaban use vs. their respective registration trials. Further research is needed to better understand appropriate dosing of patients with novel anticoagulants.
- | Savaysa (edoxaban) / Daiichi Sankyo
Trial initiation date, Trial primary completion date: Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=2000, Not yet recruiting, Sponsor: University Hospital Inselspital, Berne
Further research is needed to better understand appropriate dosing of patients with novel anticoagulants. Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: May 2021 --> Aug 2021
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Enrollment closed, Enrollment change: A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa (clinicaltrials.gov) - Sep 11, 2017
P1, N=153, Active, not recruiting, Sponsor: Portola Pharmaceuticals
Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: May 2021 --> Aug 2021 Recruiting --> Active, not recruiting | N=77 --> 153
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Retrospective data, Journal: Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. (Pubmed Central) - Sep 8, 2017
Rivaroxaban and apixaban were associated with less ICH than warfarin and both are likely associated with reductions in the combined endpoint. Further investigation to validate the numerically higher rate of ischemic stroke with apixaban versus warfarin is required.
- | rivaroxaban / Generic mfg.
New trial, Head-to-Head: SUPREME: Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD (clinicaltrials.gov) - Sep 8, 2017
P=N/A, N=438, Not yet recruiting, Sponsor: Huashan Hospital
- | rivaroxaban / Generic mfg.
Journal: Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). (Pubmed Central) - Sep 8, 2017
No significant difference was observed in the primary efficacy (stroke or non-CNS SE; adjusted interaction p value = 0.38) or safety outcome (NMCR or major bleeding; adjusted interaction p value = 0.14) between rivaroxaban and warfarin with non-DHP CCB use. In conclusion, although the overall use of non-DHP CCBs was associated with an increased risk of major bleeding and intracranial hemorrhage, the use was not associated with a significant change in the safety or efficacy of rivaroxaban compared with warfarin observed in ROCKET AF.
- |||||||||| rivaroxaban / Generic mfg.
New P2/3 trial: ADRIFT: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (clinicaltrials.gov) - Sep 5, 2017
P2/3, N=90, Not yet recruiting, Sponsor: Assistance Publique - H
- | Savaysa (edoxaban) / Daiichi Sankyo
New trial, HEOR: The DARE Warfarin CER Study (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=416000, Enrolling by invitation, Sponsor: Brigham and Women's Hospital
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
New P4 trial: COBRRA: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (clinicaltrials.gov) - Aug 29, 2017
P4, N=2760, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: CASTA-DIVA: Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban (clinicaltrials.gov) - Aug 29, 2017
P3, N=200, Recruiting, Sponsor: Assistance Publique - H
In conclusion, although the overall use of non-DHP CCBs was associated with an increased risk of major bleeding and intracranial hemorrhage, the use was not associated with a significant change in the safety or efficacy of rivaroxaban compared with warfarin observed in ROCKET AF. Trial primary completion date: May 2017 --> Mar 2018
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. (Pubmed Central) - Aug 24, 2017
Trial primary completion date: May 2017 --> Mar 2018 Among low-risk PE patients identified by using sPESI, Hestia or IMPACT, rivaroxaban was associated with significantly shorter LOS and lower hospital treatment costs versus heparin bridging to warfarin.
- || rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Retrospective data, Trial primary completion date: The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis (clinicaltrials.gov) - Aug 21, 2017
P=N/A, N=47000, Recruiting, Sponsor: Boehringer Ingelheim
Among low-risk PE patients identified by using sPESI, Hestia or IMPACT, rivaroxaban was associated with significantly shorter LOS and lower hospital treatment costs versus heparin bridging to warfarin. Trial primary completion date: Jun 2017 --> Sep 2017
- ||| Praxbind (idarucizumab) / Boehringer Ingelheim
New trial, Surgery, Claims database: Medical Need of OAC Reversal (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=62888, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | rivaroxaban / Generic mfg.
Journal: Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. (Pubmed Central) - Aug 17, 2017
Nearly 1 in 7 of the moderate-to-high-risk patients with AF enrolled in this trial was hospitalized within 2 years, and both AF and bleeding were rare causes of hospitalization. Further research is needed to determine whether care pathways directed at comorbid conditions among AF patients could reduce the need for and costs associated with hospitalization.
- | rivaroxaban / Generic mfg.
Journal: The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data. (Pubmed Central) - Aug 16, 2017
Conclusions. Our data indicates that the severity of brain hemorrhages depends on the anticoagulant class and it is more pronounced with vitamin K antagonists.
- | rivaroxaban / Bayer, Generic mfg.
Journal: Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. (Pubmed Central) - Aug 12, 2017
One patient died after developing an acute ischemic cerebrovascular insult. In conclusion, the safety and efficacy of rivaroxaban treatment for nonvalvular AF in patients with active cancer is comparable to the results of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study in the general population.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). (Pubmed Central) - Aug 12, 2017
P=N/A
In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status.
- | rivaroxaban / Generic mfg.
Journal: Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). (Pubmed Central) - Aug 10, 2017
In conclusion, in patients with atrial fibrillation treated with anticoagulant therapy, increased BMI was associated with decreased stroke risk. Warfarin and the novel anticoagulant rivaroxaban are effective in stroke prevention in all subgroups of obese patients.
- ||| rivaroxaban / Generic mfg.
New trial, Real-world evidence, Real-world: Real-world Dosing Patterns of Rivaroxaban in the United States (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=12507, Completed, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
Journal: Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. (Pubmed Central) - Jul 29, 2017
Rivaroxaban was associated with better persistence than both dabigatran (HR 0.64, 95% confidence interval [CI] 0.62-0.67) and warfarin (HR 0.62, 95% CI 0.59-0.64) and lower discontinuation than dabigatran (HR 0.61, 95% CI 0.58-0.64) and warfarin (HR 0.65, 95% CI 0.62-0.68). Real-world analysis of oral anticoagulant use may reveal whether the relatively high persistence/low discontinuation demonstrated for rivaroxaban translates into lower rates of stroke.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Biomarker, Enrollment open: DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic (clinicaltrials.gov) - Jul 28, 2017
P=N/A, N=350, Recruiting, Sponsor: University Hospital, Geneva
Real-world analysis of oral anticoagulant use may reveal whether the relatively high persistence/low discontinuation demonstrated for rivaroxaban translates into lower rates of stroke. Not yet recruiting --> Recruiting
- | Xarelto (rivaroxaban) / J&J
Trial initiation date, Trial primary completion date: Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis (clinicaltrials.gov) - Jul 19, 2017
P3, N=40, Recruiting, Sponsor: Sherief Abd-Elsalam
Not yet recruiting --> Recruiting Initiation date: Jun 2017 --> May 2014 | Trial primary completion date: Dec 2020 --> Jul 2017
- |||| rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Trial primary completion date, Surgery: PRONOMOS: PROphylaxis in NOn Major Orthopaedic Surgery (clinicaltrials.gov) - Jul 19, 2017
P3, N=4400, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Initiation date: Jun 2017 --> May 2014 | Trial primary completion date: Dec 2020 --> Jul 2017 Trial primary completion date: Jun 2017 --> Mar 2018
- | rivaroxaban / Generic mfg.
Journal: Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. (Pubmed Central) - Jul 15, 2017
P3
Trial primary completion date: Jun 2017 --> Mar 2018 We found that patients with AF and AS on oral anticoagulants may have distinctly different efficacy and safety outcomes than patients with MR or AR or no SVD.
- | Fraxiparine (nadroparin) / Aspen
Enrollment open, Trial initiation date, Metastases: Anticoagulation for Advanced Cirrhotic Patients After TIPS (clinicaltrials.gov) - Jul 14, 2017
P=N/A, N=254, Recruiting, Sponsor: Fourth Military Medical University
We found that patients with AF and AS on oral anticoagulants may have distinctly different efficacy and safety outcomes than patients with MR or AR or no SVD. Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Jun 2017
- || Trial primary completion date, Real-world evidence, Real-world: Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=88983, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Jun 2017 Trial primary completion date: Jun 2017 --> Mar 2018
- ||| rivaroxaban / Generic mfg.
New trial: Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial primary completion date: Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium (clinicaltrials.gov) - Jul 2, 2017
P4, N=110, Recruiting, Sponsor: Los Angeles Biomedical Research Institute
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Apr 2017 --> Nov 2017
- || rivaroxaban / Generic mfg.
Enrollment closed: Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (clinicaltrials.gov) - Jun 29, 2017
P=N/A, N=1503, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Apr 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- ||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment closed, Enrollment change, Surgery: BRUISECONTROL2: Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Jun 27, 2017
P3, N=663, Active, not recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=846 --> 663
- | rivaroxaban / Generic mfg.
Trial primary completion date: Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy? (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=40, Recruiting, Sponsor: Albert Einstein Healthcare Network
Recruiting --> Active, not recruiting | N=846 --> 663 Trial primary completion date: Jun 2017 --> Jun 2018
- | rivaroxaban / Generic mfg.
Journal: Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. (Pubmed Central) - Jun 25, 2017
Trial primary completion date: Jun 2017 --> Jun 2018 No abstract available
- | rivaroxaban / Generic mfg.
Journal: CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. (Pubmed Central) - Jun 23, 2017
No abstract available Higher CHA2DS2-VASc scores are associated with increased incidence of major bleeding in nonvalvular atrial fibrillation patients receiving rivaroxaban.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
New P3 trial: COVET: Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (clinicaltrials.gov) - Jun 22, 2017
P3, N=3165, Not yet recruiting, Sponsor: Duke University
- | Xarelto (rivaroxaban) / J&J
New P3 trial: Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis (clinicaltrials.gov) - Jun 20, 2017
P3, N=40, Recruiting, Sponsor: Sherief Abd-Elsalam
- ||| warfarin / Generic mfg.
New trial, Reimbursement, Medicare, Real-world evidence, Real-world: A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Na (clinicaltrials.gov) - Jun 16, 2017
P=N/A, N=36000, Completed, Sponsor: Bristol-Myers Squibb
- | Savaysa (edoxaban) / Daiichi Sankyo
New trial, Preclinical: PADOASU: In Vitro Diagnostic Test for DOAC in Urine (clinicaltrials.gov) - Jun 9, 2017
P=N/A, N=880, Not yet recruiting, Sponsor: Doasense GmbH
- || rivaroxaban / Generic mfg.
Trial primary completion date: XASSURE: Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (clinicaltrials.gov) - Jun 8, 2017
P=N/A, N=6000, Recruiting, Sponsor: Bayer
Higher CHA2DS2-VASc scores are associated with increased incidence of major bleeding in nonvalvular atrial fibrillation patients receiving rivaroxaban. Trial primary completion date: Apr 2020 --> Jun 2021
- | New trial: Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=60, Recruiting, Sponsor: University of Sao Paulo General Hospital
- ||||| Xarelto (rivaroxaban) / J&J
New P2 trial: SECRET: Study of Rivaroxaban for CeREbral Venous Thrombosis (clinicaltrials.gov) - Jun 7, 2017
P2, N=384, Not yet recruiting, Sponsor: University of British Columbia
- || apixaban / Generic mfg.
Trial primary completion date: APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study (clinicaltrials.gov) - Jun 5, 2017
P=N/A, N=18000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2020 --> Jun 2021 Trial primary completion date: Dec 2016 --> Nov 2017
- | Ciraparantag (aripazine) / Norgine, Covis Pharma
New P2 trial: Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT (clinicaltrials.gov) - Jun 1, 2017
P2, N=48, Recruiting, Sponsor: Perosphere, Inc.
- | rivaroxaban / Generic mfg.
Journal: Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. (Pubmed Central) - May 27, 2017
The relative effectiveness and safety of rivaroxaban versus warfarin were consistent across all levels of screening SBP. A single SBP may be an important factor in reducing the overall risk of stroke and SE in anticoagulated patients with AF.
- | rivaroxaban / Generic mfg.
Journal: Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. (Pubmed Central) - May 27, 2017
Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD. Although these findings may reflect unmeasured clinical factors, further investigation is warranted to determine optimal aspirin use in patients with AF.
- | Savaysa (edoxaban) / Daiichi Sankyo
Enrollment open: DANNOAC-AF: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (clinicaltrials.gov) - May 25, 2017
P4, N=11000, Recruiting, Sponsor: Danish Heart Foundation
Although these findings may reflect unmeasured clinical factors, further investigation is warranted to determine optimal aspirin use in patients with AF. Not yet recruiting --> Recruiting
- | Savaysa (edoxaban) / Daiichi Sankyo
Enrollment open: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (clinicaltrials.gov) - May 25, 2017
P4, N=5000, Recruiting, Sponsor: Danish Heart Foundation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
Enrollment open, Surgery: PRO-LAPSII: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. (clinicaltrials.gov) - May 23, 2017
P3, N=646, Recruiting, Sponsor: Fadoi Foundation, Italy
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment closed, Trial primary completion date: Use of Direct Oral Anticoagulants in UK (clinicaltrials.gov) - May 23, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Aug 2017
- | Savaysa (edoxaban) / Daiichi Sankyo
New P3 trial: Start or STop Anticoagulants Randomised Trial (SoSTART) (clinicaltrials.gov) - May 15, 2017
P3, N=800, Not yet recruiting, Sponsor: University of Edinburgh
- | rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
Journal: Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. (Pubmed Central) - May 14, 2017
In the absence of these tests, TT or APTT is recommended over PT/INR for assessment of dabigatran, and PT/INR is recommended over APTT for detection of factor Xa inhibitors. Time since last dose, the presence or absence of drug interactions, and renal and hepatic function should impact clinical estimates of anticoagulant effect in a patient for whom laboratory test results are not available.